Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $81.50.

Several research firms have recently commented on RARE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Wells Fargo & Company cut their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Finally, Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th.

Ultragenyx Pharmaceutical Trading Down 0.7%

Ultragenyx Pharmaceutical stock opened at $31.45 on Friday. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $57.99. The stock’s 50 day moving average is $29.75 and its 200-day moving average is $33.06. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -5.69 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. During the same quarter in the prior year, the business earned ($1.52) earnings per share. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its position in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $55,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at $57,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at $59,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.